4Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose flueonazole versus flueonazole alone for prophylaxis of fungal infetions in adult patients undergoing a bone marrow or pecipheral stem cell transplant antimicroh[J].igents Chemother, 2005, 49(4):1 331.
5Kishino S, Ohno K, Shimamura T, et al. Optimal prophylactic dosage and disposition of micafungin in living donor liver recipeents[J].Clin Transplant, 2004,18(6): 676.
6Niwa T, Yokota Y, Tokunaga A, et at.Tissue distribution after intravenous dosing of micafungin, an antifungal to drug, to rats[J]. Biol Pharm Bull, 2004, 27(7) :1 154.
7Hiraoka T, Wakabayashi T, Kaji Y, et al. Toxicologfcale-valuation of micafungin ophthalmic solution in rabbit eyes[J].J Ocul Pharmacol Ther, 2005, 21 (2):149.
8Pacetti S A, Gelone S P. Caspofungin acetate for treatemnt of invasive fungal infetions[J].inn Pharmacother, 2003,37(1):90.
9Dimitos P, Kontoyiannis, Lewis R E, et al.Caspofungin versus liposomalamphototericin B for empirical therapy[J].N Engl J Med, 2005, 352 (1) : 410.
10A rikan S, Lozano C M, Paerznick V, et al. ln vitro susceptibility testing methods for caspofungin againt spergillus and Fusarium isolates[J].Antimicrob Agent Chemother, 2001,45(1):327.
